Skip to main content
. 2021 Oct 2;144:112276. doi: 10.1016/j.biopha.2021.112276

Fig. 3.

Fig. 3

Scheme of the investigated anti-inflammatory therapeutics. Dornase alfa acts against NETs, baricitinib and ruxolitinib inhibit JAK/STAT signaling, losartan and C21 leverage the angiotensin-renin system to reduce inflammation, and methylprednisolone and dexamethasone act as anti-inflammatories through the action of the glucocorticoid receptor in the cytoplasm. Heparin blocks blood clotting by inhibiting clotting factors upstream of thrombin production.